当前位置： SCI文献检索 > ALIMENTARY PHARMACOLOGY & THERAPEUTICS期刊下所有文献 > Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer. Pantoprazole-Duodenal Ulcer-Study Group.

Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer. Pantoprazole-Duodenal Ulcer-Study Group.

Abstract：

BACKGROUND:Pantoprazole is a new substituted benzimidazole that blocks the H+/K(+)-ATPase in the gastric mucosa and thus inhibits acid secretion. METHODS:Efficacy and tolerability of pantoprazole (40 mg at breakfast) and ranitidine (300 mg at bedtime) in the treatment of uncomplicated acute duodenal ulcer were compared in a double-blind randomized multicentre trial. RESULTS:Of 202 outpatients who entered the study, 185 terminated the treatment without violation of the protocol. After 2 weeks of treatment, healing rates (protocol correct) with pantoprazole and ranitidine were 81 and 53%, respectively (P < 0.001), the corresponding results after 4 weeks were 97 and 83% (P < 0.01). Pantoprazole was more effective with respect to symptom relief. Both treatments were well tolerated. CONCLUSION:Pantoprazole 40 mg at breakfast is superior to ranitidine 300 mg at bedtime in the short-term treatment of acute, uncomplicated duodenal ulcer.

journal_name

Aliment Pharmacol Ther

journal_title

Alimentary pharmacology & therapeutics

authors

Judmaier G,Koelz HR

doi

10.1111/j.1365-2036.1994.tb00163.x

subject

Has Abstract

pub_date

1994-02-01 00:00:00

pages

81-6

issue

1

eissn

0269-2813

issn

1365-2036

journal_volume

8

pub_type

临床试验,杂志文章,多中心研究,随机对照试验

相关文献

ALIMENTARY PHARMACOLOGY & THERAPEUTICS文献大全
  • Review article: colorectal carcinoma and inflammatory bowel disease.

    abstract：:The risk of colorectal cancer for any patient with ulcerative colitis is estimated to be 2% after 10 years, 8% after 20 years and 18% after 30 years of disease. The relative risk of colorectal cancer in Crohn's colitis is approximately 5.6 and should raise the same concerns as in ulcerative colitis. Risk factors for c...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2004.02046.x

    authors： Eaden J

    更新日期：2004-10-01 00:00:00

  • High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates.

    abstract：BACKGROUND:Strong acid inhibition using esomeprazole increases cure rates with triple therapy and 10-day treatments are more effective than 7-day ones. The combination of amoxicillin plus metronidazole at full doses, and using a physiologically-correct schedule three times a day, and has been shown to overcome metronid...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2012.05137.x

    authors： Sánchez-Delgado J,García-Iglesias P,Castro-Fernández M,Bory F,Barenys M,Bujanda L,Lisozain J,Calvo MM,Torra S,Gisbert JP,Calvet X

    更新日期：2012-07-01 00:00:00

  • Proton pump inhibitors: better acid suppression when taken before a meal than without a meal.

    abstract：BACKGROUND:Proton pump inhibitors including omeprazole and lansoprazole inhibit gastric acid secretion by selectively and non-competitively inactivating the H+, K+ ATPase molecules of the parietal cell, but possibly only those that are actively secreting acid. This might imply that stimulation of acid secretion by a me...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1365-2036.2000.00829.x

    authors： Hatlebakk JG,Katz PO,Camacho-Lobato L,Castell DO

    更新日期：2000-10-01 00:00:00

  • Review article: the management of acute variceal bleeding.

    abstract：:Variceal haemorrhage is a common medical emergency with a high mortality (30-50%). Adequate resuscitation is vital, and once stabilised the patient should be moved to a high-dependency area. Antibiotics reduce mortality, and the vasoactive drug terlipressin should be administered if early endoscopy is unavailable. Ear...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1046/j.1365-2036.2003.01664.x

    authors： Ferguson JW,Tripathi D,Hayes PC

    更新日期：2003-08-01 00:00:00

  • Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen.

    abstract：BACKGROUND:The duration of Helicobacter pylori eradication regimens has decreased to 1 week with cure rates of over 90%. This can be attributed to the use of triple drug regimens including potent inhibitors of gastric acid secretion and clarithromycin. There is no theoretical reason why shorter regimens should not be p...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1365-2036.1999.00574.x

    authors： Grimley CE,Penny A,O'sullivan M,Shebani M,Lismore JR,Cross R,Illing RC,Loft DE,Nwokolo CU

    更新日期：1999-07-01 00:00:00

  • High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection.

    abstract：BACKGROUND:Helicobacter pylori infection may persist after both first- and second-line current treatments. AIM:To assess the efficacy of a third-line, culture-guided treatment approach for the eradication of H. pylori. METHODS:Patterns of resistance were analysed in H. pylori isolates from 94 consecutive patients in ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2004.01910.x

    authors： Cammarota G,Martino A,Pirozzi G,Cianci R,Branca G,Nista EC,Cazzato A,Cannizzaro O,Miele L,Grieco A,Gasbarrini A,Gasbarrini G

    更新日期：2004-04-01 00:00:00

  • Review article: current management of renal dysfunction in the cirrhotic patient.

    abstract：:The United Network for Organ Sharing database revealed that over the last 4-5 years, an average of 1800 patients were removed from the cadaveric waiting list annually because of patients' death and an additional 400-500 were removed from the list because of the severity of their illnesses. The pre-transplant evaluatio...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2005.02357.x

    authors： Pham PT,Pham PC,Rastogi A,Wilkinson AH

    更新日期：2005-04-15 00:00:00

  • Review article: approaches to Barrett's oesophagus treatment-the role of proton pump inhibitors and other interventions.

    abstract：:Despite implementation of screening and surveillance strategies, a significantly large number of patients with Barrett's oesophagus remain undiagnosed. In those who are identified, the management options include acid reduction therapies with proton pump inhibitors or anti-reflux surgery. Endoscopic ablative therapies ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.0953-0673.2004.01839.x

    authors： Jankowski J,Sharma P

    更新日期：2004-02-01 00:00:00

  • Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole.

    abstract：BACKGROUND:Studies to date have not directly compared the pharmacodynamic efficacies of different proton pump inhibitors in controlling intragastric acidity in patients treated with non-steroidal anti-inflammatory drugs. AIM:To compare acid suppression with once-daily esomeprazole 40 mg, lansoprazole 30 mg and pantopr...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1365-2036.2006.02867.x

    authors： Goldstein JL,Miner PB Jr,Schlesinger PK,Liu S,Silberg DG

    更新日期：2006-04-15 00:00:00

  • Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.

    abstract：BACKGROUND:Sofosbuvir, an oral NS5B nucleotide polymerase inhibitor, is indicated for the treatment of patients infected with hepatitis C virus (HCV). AIM:To evaluate the long-term health economic outcomes of sofosbuvir + pegylated interferon alfa/ribavirin (pegIFN/RBV) compared with current treatments in patients inf...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.12871

    authors： Saab S,Gordon SC,Park H,Sulkowski M,Ahmed A,Younossi Z

    更新日期：2014-09-01 00:00:00

  • Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis.

    abstract：BACKGROUND:This randomized, double-blind, multicentre study compared lansoprazole with placebo for symptomatic relief of patients with non-erosive gastro-oesophageal reflux disease (GERD). METHODS:214 patients with symptomatic, non-erosive GERD (moderate to severe daytime and/or night-time heartburn greater than half ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1046/j.1365-2036.1999.00558.x

    authors： Richter JE,Kovacs TO,Greski-Rose PA,Huang section sign B,Fisher R

    更新日期：1999-06-01 00:00:00

  • Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.

    abstract：BACKGROUND:Programmed cell death protein-1-targeted immunotherapy has shown promising results in phase II studies of hepatocellular carcinoma. AIM:To evaluate safety and efficacy of nivolumab and pembrolizumab in an international, multicentre, real-world cohort of patients with advanced hepatocellular carcinoma. METH...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1111/apt.15245

    authors： Scheiner B,Kirstein MM,Hucke F,Finkelmeier F,Schulze K,von Felden J,Koch S,Schwabl P,Hinrichs JB,Waneck F,Waidmann O,Reiberger T,Müller C,Sieghart W,Trauner M,Weinmann A,Wege H,Trojan J,Peck-Radosavljevic M,Vogel A

    更新日期：2019-05-01 00:00:00

  • Review article: esomeprazole in the treatment of Helicobacter pylori.

    abstract：:Proton pump inhibitor-based triple therapy is the most commonly used treatment for eradication of Helicobacter pylori, with pooled eradication rates of approximately 90%. In the USA, per protocol eradication rates with 10-day proton pump inhibitor-based triple therapy are approximately 85%. Esomeprazole, a new proton ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1046/j.1365-2036.16.s4.13.x

    authors： Laine L

    更新日期：2002-07-01 00:00:00

  • H2-antagonist maintenance therapy versus Helicobacter pylori eradication in patients with chronic duodenal ulcer disease: a prospective study.

    abstract：BACKGROUND:Few outcome studies directly compare Helicobacter pylori eradication therapy with maintenance H2-antagonist therapy in duodenal ulcer disease. AIM:To examine prospectively the efficacy of H. pylori eradication therapy with ranitidine maintenance therapy over 1 year in patients with confirmed chronic duodena...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1365-2036.1998.00391.x

    authors： Prach AT,Malek M,Tavakoli M,Hopwood D,Senior BW,Murray FE

    更新日期：1998-09-01 00:00:00

  • Review article: the incidence and risk factors for irritable bowel syndrome in population-based studies.

    abstract：BACKGROUND:In the absence of prior gastrointestinal infection, the risk factors for irritable bowel syndrome (IBS) are not well established. AIM:To identify the incidence and risk factors for IBS in general population samples METHODS: Narrative review of population-based studies. Electronic databases were searched usi...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/apt.15396

    authors： Creed F

    更新日期：2019-09-01 00:00:00

  • The effects of fasting on 24-h gastric secretion of patients with duodenal ulcers resistant to ranitidine.

    abstract：:We compared the effects of fasting and feeding on the antisecretory actions of ranitidine in 19 patients whose duodenal ulcers remained unhealed or relapsed despite treatment with the drug. Nine of the patients received, and continued with, 150 mg ranitidine b.d. and 10 took 300 mg ranitidine b.d. In all patients, gas...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.1989.tb00238.x

    authors： Johnston DA,Wormsley KG

    更新日期：1989-10-01 00:00:00

  • There are some benefits for eradicating Helicobacter pylori in patients with non-ulcer dyspepsia.

    abstract：BACKGROUND:The relationship between Helicobacter pylori infection and non-ulcer dyspepsia is not established. AIM:To determine whether eradication of H. pylori might be of benefit in non-ulcer dyspepsia patients. METHODS:We randomly assigned 129 H. pylori infected patients with severe epigastric pain, without gastro-...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1046/j.1365-2036.2001.01014.x

    authors： Bruley Des Varannes S,Fléjou JF,Colin R,Zaïm M,Meunier A,Bidaut-Mazel C

    更新日期：2001-08-01 00:00:00

  • Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease; the importance of an elevated mean platelet volume.

    abstract：BACKGROUND:Atherosclerotic cardiovascular disease is a key cause of morbidity in non-alcoholic fatty liver disease (NAFLD) but appropriate means to predict major acute cardiovascular events (MACE) are lacking. AIM:To design a bespoke cardiovascular risk score in NAFLD. METHODS:A retrospective derivation (2008-2016, 3...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.15192

    authors： Abeles RD,Mullish BH,Forlano R,Kimhofer T,Adler M,Tzallas A,Giannakeas N,Yee M,Mayet J,Goldin RD,Thursz MR,Manousou P

    更新日期：2019-04-01 00:00:00

  • Neurokinin-1 receptor antagonism in a human model of visceral hypersensitivity.

    abstract：BACKGROUND:Substance P acting via the neurokinin-1 receptor is involved in the development of hyperalgesia, although studies using neurokinin-1 receptor antagonists (NK-1RA) in human somatic pain have been disappointing. AIM:To evaluate whether Substance P is involved in the development of human visceral pain/hyperalg...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.2006.03190.x

    authors： Willert RP,Hobson AR,Delaney C,Hicks KJ,Dewit OE,Aziz Q

    更新日期：2007-02-01 00:00:00

  • Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation.

    abstract：BACKGROUND:Lubiprostone (8 μg b.d.) received US Food and Drug Administration (FDA) approval in 2008 for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) in women aged ≥18 years. In 2012, the FDA issued new guidance for IBS-C clinical trials, recommending a composite endpoint incorporating both...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,随机对照试验

    doi：10.1111/apt.13807

    authors： Chang L,Chey WD,Drossman D,Losch-Beridon T,Wang M,Lichtlen P,Mareya S

    更新日期：2016-11-01 00:00:00

  • Underutilization of gastroprotection for at-risk patients undergoing percutaneous coronary intervention: Spain compared with the United States.

    abstract：BACKGROUND:Proton pump inhibitors (PPIs) are the preferred agents for the prevention of aspirin-associated upper gastrointestinal bleeding (UGIB). Data are limited to determine whether PPIs are being used to reduce UGIB risk. AIM:To evaluate the implementation of PPI treatment to reduce the GI risk in two cardiology c...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1111/j.1365-2036.2010.04393.x

    authors： Casado-Arroyo R,Scheiman JM,Polo-Tomas M,Saini SD,Del Rio A,Guastello E,Lanas A

    更新日期：2010-09-01 00:00:00

  • Coeliac disease: a biopsy is not always necessary for diagnosis.

    abstract：BACKGROUND:In view of the high diagnostic accuracy of immunoglobulin-A-tissue transglutaminase antibodies for detecting coeliac disease, we have explored whether a small bowel biopsy is always required to establish the diagnosis. AIM:To define the transglutaminase antibody level giving a positive predictive value for ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2008.03609.x

    authors： Hill PG,Holmes GK

    更新日期：2008-04-01 00:00:00

  • Characterisation of the gastrointestinal mucosa-associated microbiota: a novel technique to prevent cross-contamination during endoscopic procedures.

    abstract：BACKGROUND:The mucosa-associated microbiota appears to be highly relevant to host-microbe interactions in the gastrointestinal (GI) tract. Thus, precise characterisation of the mucosa-associated microbiota may provide important insights for diagnostic and therapeutic development. However, for technical reasons, mucosal...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.13622

    authors： Shanahan ER,Zhong L,Talley NJ,Morrison M,Holtmann G

    更新日期：2016-06-01 00:00:00

  • Changing patterns of sedation use for routine out-patient diagnostic gastroscopy between 1989 and 1998.

    abstract：BACKGROUND:Knowledge of sedation trends for upper gastrointestinal endoscopy is important for health service planning, particularly in view of rapidly increasing demands on endoscopy services. However, no data are available on sedation trends in Britain over the past 10 years. AIM:To determine sedation use for routine...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.2001.00912.x

    authors： Mulcahy HE,Hennessy E,Connor P,Rhodes B,Patchett SE,Farthing MJ,Fairclough PD

    更新日期：2001-02-01 00:00:00

  • Diffusion-weighted magnetic resonance imaging is effective to detect ileocolonic ulcerations in Crohn's disease.

    abstract：BACKGROUND:Magnetic resonance entero-colonography enables accurate assessment of ileocolonic Crohn's disease, but the need for bowel cleansing and rectal enema limits considerably its use in daily practice. AIM:We evaluated the accuracy of diffusion-weighted magnetic resonance entero-colonography with neither bowel cl...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.13287

    authors： Buisson A,Hordonneau C,Goutte M,Boyer L,Pereira B,Bommelaer G

    更新日期：2015-08-01 00:00:00

  • Do mucosal defensive agents improve the cure rate when used with dual or triple therapy regimens for eradicating Helicobacter pylori infection?

    abstract：BACKGROUND:Some of mucosal defensive agents have anti-Helicobacter pylori activities. However, their effectiveness in eradicating H. pylori infection has not been evaluated. AIM:To assess the additive effect of mucosal defensive agents in eradication regimens using statistical analysis. METHODS:Pertinent studies were...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,meta分析

    doi：10.1046/j.1365-2036.2000.00692.x

    authors： Hojo M,Miwa H,Kikuchi S,Sato N

    更新日期：2000-02-01 00:00:00

  • The influence of common gene variants of the xenobiotic receptor (PXR) in genetic susceptibility to intrahepatic cholestasis of pregnancy.

    abstract：BACKGROUND:The xenobiotic nuclear pregnane X receptor is implicated in many physiological pathways and diseases, including bile acid detoxification and cholestasis. Aim To estimate the contribution of common gene variants of the xenobiotic receptor (pregnane X receptor, PXR) to genetic susceptibility to intrahepatic ch...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2009.04210.x

    authors： Castaño G,Burgueño A,Fernández Gianotti T,Pirola CJ,Sookoian S

    更新日期：2010-03-01 00:00:00

  • Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease.

    abstract：BACKGROUND:Combination treatment with azathioprine for 6-12 months is the preferred strategy for starting infliximab due to improved pharmacokinetics. However, optimised infliximab monotherapy with proactive dose escalations in case of low trough levels is a safer but under-studied alternative. AIM:To compare the clin...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.15179

    authors： Drobne D,Kurent T,Golob S,Švegl P,Rajar P,Hanžel J,Koželj M,Novak G,Smrekar N,Ferkolj I,Štabuc B

    更新日期：2019-04-01 00:00:00

  • Occurrence and risk factors for benign epithelial gastric polyps in atrophic body gastritis on diagnosis and follow-up.

    abstract：BACKGROUND:Benign epithelial gastric polyps have been reported to be more common in atrophic body gastritis. The role of Helicobacter pylori infection in the induction of gastric atrophy is well-known. The development of hyperplastic polyps may be in relation to H. pylori infection. AIM:To investigate occurrence of be...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2005.02399.x

    authors： Di Giulio E,Lahner E,Micheletti A,Milione M,D'Ambra G,Bordi C,Delle Fave G,Annibale B

    更新日期：2005-03-01 00:00:00

  • The sequential organ failure assessment (SOFA) score is an effective triage marker following staggered paracetamol (acetaminophen) overdose.

    abstract：BACKGROUND:The sequential organ failure assessment (SOFA) score is an effective triage marker following single time point paracetamol (acetaminophen) overdose, but has not been evaluated following staggered (multiple supratherapeutic doses over >8 h, resulting in cumulative dose of >4 g/day) overdoses. AIM:To evaluate...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2012.05102.x

    authors： Craig DG,Zafar S,Reid TW,Martin KG,Davidson JS,Hayes PC,Simpson KJ

    更新日期：2012-06-01 00:00:00